The funding seeks to advance the development of a new companion diagnostic test that involves a simple blood sample. Credit: Hush Naidoo Jade Photography on Unsplash.

OSE Immunotherapeutics has received non-dilutive funding from Bpifrance – Direction Régionale de Nantes to develop a companion diagnostic test for a Phase III trial of the Tedopi vaccine as a second-line treatment of non-small cell lung cancer (NSCLC).

The €1.5m ($1.63m) funding was provided as part of the R&D Innovation Loan programme.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It expects to advance the development of a new companion diagnostic test that involves a simple blood sample.

This diagnostic is a test for a predictive immunological biomarker to recognise HLA-A2 genotype patients who biologically respond to Tedopi.

It will be used to enrol the patient subpopulation in the proposed registration Phase III trial of Tedopi.

This final clinical development stage aims to verify the efficacy and safety of Tedopi in second-line treatment post-immune checkpoint inhibitor failure in NSCLC patients who are HLA-A2 positive.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

OSE Immunotherapeutics CEO Nicolas Poirier said: “We warmly thank Bpifrance – Direction Régionale de Nantes for funding the development of this unique companion diagnostic test to accelerate the final clinical development phase of our cancer vaccine Tedopi in preparation to support the regulatory registration in advanced NSCLC for the HLA-A2 patient subpopulation.”

NSCLC is estimated to account for 85% of all lung cancers and the HLA-A2 phenotype represents nearly 45% of the population.

Annually, up to 100,000 patients could benefit from Tedopi in seven major markets across Europe, China Japan and the US.

Tedopi, which already obtained an orphan drug status designation in the US, is considered a precision medicine for patients with HLA-A2 in Europe.